Da metaboliseringen og udskillelsen af natriumphenylbutyrat sker via lever og nyre, skal AMMONAPS anvendes med forsigtighed til patienter med lever - eller nyreinsufficiens.
Since the metabolism and excretion of sodium phenylbutyrate involves the liver and kidneys, AMMONAPS should be used with caution in patients with hepatic or renal insufficiency.